Hand Osteoarthritis: investigating Pain Effects of estrogen-containing therapy (HOPE-e): a protocol for a feasibility randomised placebo-controlled trial

Ioana R Marian, Megan Goff, Jennifer A E Williams, Malvika Gulati, Mae Chester-Jones, Anne Francis, Marion Watson, Tonia L Vincent, Sue Woollacott, Charles Mackworth-Young, Victoria Glover, Dominic Furniss, Matthew Gardiner, Sarah E Lamb, Katy Vincent, Vicki S Barber, Joanna Black, Susan J Dutton, Fiona E Watt, Ioana R Marian, Megan Goff, Jennifer A E Williams, Malvika Gulati, Mae Chester-Jones, Anne Francis, Marion Watson, Tonia L Vincent, Sue Woollacott, Charles Mackworth-Young, Victoria Glover, Dominic Furniss, Matthew Gardiner, Sarah E Lamb, Katy Vincent, Vicki S Barber, Joanna Black, Susan J Dutton, Fiona E Watt

Abstract

Background: Hand osteoarthritis (OA) is a common condition, causing pain, stiffness and reduced quality of life. Incidence is higher amongst women, particularly around the age of the menopause. Whilst the relationship between sex hormones and OA has been studied in vitro, in epidemiological studies and in clinical trials of hormone replacement therapy (HRT), this study is the first to investigate the effect of estrogen-containing therapy on hand pain in post-menopausal women with symptomatic hand OA in a randomised study design.

Methods: This is a feasibility study of a double-blinded placebo-controlled intervention with 1:1 randomisation to either a combination of conjugated estrogens 0.45 mg and bazedoxifene acetate 20 mg (Duavive) or placebo. The target population is post-menopausal women with symptomatic hand OA, aiming to recruit 60-90 study participants. The primary objective is to assess the feasibility of a future fully powered randomised controlled trial (RCT). Participants will take the study medication for 24 weeks and be followed up for 28 weeks after randomisation. The primary outcomes used to determine feasibility are eligible participant identification rates and routes; recruitment, randomisation and retention rates of eligible participants; study medication compliance; and the likelihood of unintentional unblinding. Secondary outcomes include measures of hand pain, function, appearance and menopausal symptoms. An end of study questionnaire and focus groups will help to refine the final protocol for a full study.

Discussion: Identifying new treatments for symptomatic hand OA is a recognised research priority. The study will help us to understand whether there are sufficient interested and eligible individuals in this target population who would consider HRT for their hand symptoms. It will provide proof-of-concept RCT data on the effects of HRT on hand pain and other clinically relevant outcomes in this population. The study will gain valuable information on the feasibility of a full RCT and how best to run this. The findings will be published in a peer-reviewed journal and presented at a relevant conference.

Trial registration: ISRCTN12196200 registered on 15 January 2019.

Keywords: Clinical trial; Estrogen; Feasibility; Hand osteoarthritis; Hormone replacement therapy.

Conflict of interest statement

The authors declare they have no competing interests.

Figures

Fig. 1
Fig. 1
Study flow chart
Fig. 2
Fig. 2
CONSORT pilot and feasibility trials flow diagram schematic

References

    1. Bijlsma JWJ, Berenbaum F, Lafeber FPJG. Osteoarthritis: An update with relevance for clinical practice. Lancet. 2011;377(9783):2115–2126. doi: 10.1016/S0140-6736(11)60243-2.
    1. Zhang Y, Niu J, Kelly-Hayes M, Chaisson CE, Aliabadi P, Felson DT. Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: The framingham study. Am J Epidemiol. 2002;156(11):1021–1027. doi: 10.1093/aje/kwf141.
    1. Marshall M, Watt FE, Vincent TL, Dziedzic K. Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management. Nat Rev Rheumatol. 2018;14(11):641–656. doi: 10.1038/s41584-018-0095-4.
    1. Kloppenburg M, Kroon FPB, Blanco FJ, Doherty M, Dziedzic KS, Greibrokk E, Haugen IK, Herrero-Beaumont G, Jonsson H, Kjeken I, Maheu E, Ramonda R, Ritt MJPF, Smeets W, Smolen JS, Stamm TA, Szekanecz Z, Wittoek R, Carmona L. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16–24. doi: 10.1136/annrheumdis-2018-213826.
    1. Heyworth BE, Lee JH, Kim PD, Lipton CB, Strauch RJ, Rosenwasser MP. Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a prospective, randomized, double-blinded clinical trial. J Hand Surg Am. 2008;33(1):40–48. doi: 10.1016/j.jhsa.2007.10.009.
    1. Meenagh GK, Patton J, Kynes C, Wright GD. A randomised controlled trial of intra-articular corticosteroid injection of the carpometacarpal joint of the thumb in osteoarthritis. Ann Rheum Dis. 2004;63(10):1260–1263. doi: 10.1136/ard.2003.015438.
    1. Kroon FPB, Rubio R, Schoones JW, Kloppenburg M. Intra-articular therapies in the treatment of hand osteoarthritis: a systematic literature review. Drugs Aging. 2016;33(2):119–133. doi: 10.1007/s40266-015-0330-5.
    1. Conaghan PG, Dickson J, Grant RL. Guidelines: Care and management of osteoarthritis in adults: Summary of NICE guidance. Bmj. 2008;336(7642):502–503. doi: 10.1136/.
    1. Moe RH, Kjeken I, Uhlig T, Hagen KB. There is inadequate evidence to determine the effectiveness of nonpharmacological and nonsurgical interventions for hand osteoarthritis: an overview of high-quality systematic reviews. Phys Ther. 2009;89(12):1363–1370. doi: 10.2522/ptj.20080398.
    1. Punzi L, Ramonda R, Sfriso P. Erosive osteoarthritis. Best Pract Res Clin Rheumatol. 2004;18(5):739–758. doi: 10.1016/j.berh.2004.05.010.
    1. Arthritis Research UK. Osteoarthritis in General Practice: Data and Perspectives. University of Keele; 2013. .
    1. Oliveria SA, Felson DT, Reed JI, Cirillo PA, Walker AM. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum. 1995;38(8):1134–1141. doi: 10.1002/art.1780380817.
    1. Watt FE. Hand osteoarthritis, menopause and menopausal hormone therapy. Maturitas. 2016;83:13–18. doi: 10.1016/j.maturitas.2015.09.007.
    1. Watt FE, Carlisle K, Kennedy D, Vincent TL. Menopause and hormone replacement therapy are important aetiological factors in hand osteoarthritis: results from a cross-sectional study in secondary care. Maturitas. 2015;81(1):128. doi: 10.1016/j.maturitas.2015.02.092.
    1. Burkard T, Rauch M, Spoendlin J, Prieto-Alhambra D, Jick SS, Meier CR. Risk of hand osteoarthritis in new users of hormone replacement therapy: a nested case-control analysis. Maturitas. 2020;132:17–23. doi: 10.1016/j.maturitas.2019.11.006.
    1. Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007;16(3):223–234. doi: 10.1016/j.breast.2007.01.011.
    1. Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, Abramson VG, Chakravarthy AB, Friedman DL, Cella DF. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer. 2013;119:2375-82. 10.1002/cncr.28016.
    1. Smith YR, Stohler CS, Nichols TE, Bueller JA, Koeppe RA, Zubieta JK. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci. 2006;26(21):5777–5785. doi: 10.1523/JNEUROSCI.5223-05.2006.
    1. Martin VT. Ovarian hormones and pain response: A review of clinical and basic science studies. Gend Med. 2009;6(PART 2):168–192. doi: 10.1016/j.genm.2009.03.006.
    1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. J Am Med Assoc. 2002;288(3):321–333. doi: 10.1001/jama.288.3.321.
    1. Komm BS, Mirkin S. An overview of current and emerging SERMs. J Steroid Biochem Mol Biol. 2014;143:207–222. doi: 10.1016/j.jsbmb.2014.03.003.
    1. Davis SR, Lambrinoudaki I, Lumsden M, Mishra GD, Pal L, Rees M, Santoro N, Simoncini T. Menopause. Nat Rev Dis Prim. 2015;1(1):15004. doi: 10.1038/nrdp.2015.4.
    1. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–68.
    1. Utian WH. A decade post WHI, menopausal hormone therapy comes full circle - Need for independent commission. Climacteric. 2012;15(4):320–325. doi: 10.3109/13697137.2012.678916.
    1. Prentice RL. Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med. 2014;32(6):419–425. doi: 10.1055/s-0034-1384624.
    1. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JAV, Santen RJ. Treatment of symptoms of the menopause: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011. doi: 10.1210/jc.2015-2236.
    1. National Institute for Health and Care Excellence. Menopause: Diagnosis and Management. Nice. 2015;
    1. Chlebowski RT, Cirillo DJ, Eaton CB, Stefanick ML, Pettinger M, Carbone LD, Johnson KC, Simon MS, Woods NF, Wactawski-Wende J. Estrogen alone and joint symptoms in the Women’s Health Initiative randomized trial. Menopause. 2018;25(11):1313–1320. doi: 10.1097/GME.0000000000001235.
    1. de Klerk BM, Schiphof D, Groeneveld FPMJ, Koes BW, van Osch GJVM, van Meurs JBJ, Bierma-Zeinstra SMA. Limited evidence for a protective effect of unopposed oestrogen therapy for osteoarthritis of the hip: A systematic review. Rheumatology. 2009;48(2):104–112. doi: 10.1093/rheumatology/ken390.
    1. Cirillo DJ, Wallace RB, Wu L, Yood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the women’s health initiative. Arthritis Rheum. 2006;54(10):3194–3204. doi: 10.1002/art.22138.
    1. Spector TD, Nandra D, Hart DJ, Doyle DV. Is hormone replacement therapy protective for hand and knee osteoarthritis in women?: The Chingford Study. Ann Rheum Dis. 1997;56(7):432–434. doi: 10.1136/ard.56.7.432.
    1. Maheu E, Dreiser RL, Guillou GB, Dewailly J. Hand osteoarthritis patients characteristics according to the existence of a hormone replacement therapy. Osteoarthr Cartil. 2000;8(SUPPL. A):S33–S37. doi: 10.1053/joca.2000.0334.
    1. Lugo L, Villalvilla A, Largo R, Herrero-Beaumont G, Roman-Blas JA. Selective estrogen receptor modulators (SERMs): New alternatives for osteoarthritis? Maturitas. 2014;77(4):380–384. doi: 10.1016/j.maturitas.2014.01.016.
    1. Sniekers YH, Weinans H, Bierma-Zeinstra SM, van Leeuwen JPTM, van Osch GJVM. Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment - a systematic approach. Osteoarthr Cartil. 2008;16(5):533–541. doi: 10.1016/j.joca.2008.01.002.
    1. Christgau S, Tankó LB, Cloos PAC, Mouritzen U, Christiansen C, Delaissé JM, Høegh-Andersen P. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM) Menopause. 2004;11(5):508–518. doi: 10.1097/01.WCB.0000121484.18437.98.
    1. Fujita T, Fujii Y, Munezane H, Ohue M, Takagi Y. Analgesic effect of raloxifene on back and knee pain in postmenopausal women with osteoporosis and/or osteoarthritis. J Bone Miner Metab. 2010;28(4):477–484. doi: 10.1007/s00774-009-0155-6.
    1. Lobo RA, Pinkerton JAV, Gass MLS, Dorin MH, Ronkin S, Pickar JH, Constantine G. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009;92(3):1025–1038. doi: 10.1016/j.fertnstert.2009.03.113.
    1. Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. Maturitas. 2014;78(3):212–218. doi: 10.1016/j.maturitas.2014.04.008.
    1. Palacios S, Currie H, Mikkola TS, Dragon E. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: A practical guide. Maturitas. 2015;80(4):435–440. doi: 10.1016/j.maturitas.2015.01.003.
    1. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials. 2004;25(2):143–156. doi: 10.1016/j.cct.2003.10.016.
    1. Kloppenburg M, Maheu E, Kraus VB, Cicuttini F, Doherty M, Dreiser RL, Henrotin Y, Jiang GL, Mandl L, Martel-Pelletier J, Nelson AE, Neogi T, Pelletier JP, Punzi L, Ramonda R, Simon LS, Wang S. OARSI Clinical Trials Recommendations: design and conduct of clinical trials for hand osteoarthritis. Osteoarthr Cartil. 2015;23(5):772–786. doi: 10.1016/j.joca.2015.03.007.
    1. Dreiser RL, Maheu E, Guillou GB, Caspard H, Grouin JM. Validation of an algofunctional index for osteoarthritis of the hand. Rev Rhum. 1995;62(6 SUPPL. 1):43S–53S.
    1. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip and pinch strength evaluations. J Hand Surg Am. 1984;9(2):222–226. doi: 10.1016/S0363-5023(84)80146-X.
    1. Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Heal. 2012;15(5):708–715. doi: 10.1016/j.jval.2012.02.008.
    1. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, Swinburn P, Busschbach J. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–1727. doi: 10.1007/s11136-012-0322-4.
    1. Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas. 2005;50(3):209–221. doi: 10.1016/j.maturitas.2004.06.015.
    1. Radtke JV, Terhorst L, Cohen SM. The menopause-specific quality of life questionnaire: Psychometric evaluation among breast cancer survivors. Menopause. 2011;18(3):289–295. doi: 10.1097/gme.0b013e3181ef975a.
    1. Greene JG. Constructing a standard climacteric scale. Maturitas. 1998;29(1):25–31. doi: 10.1016/S0378-5122(98)00025-5.
    1. Chung KC, Pillsbury MS, Walters MR, Hayward RA. Reliability and validity testing of the Michigan Hand Outcomes Questionnaire. J Hand Surg Am. 1998;23(4):575–587. doi: 10.1016/S0363-5023(98)80042-7.
    1. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WSM, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: Defining standard protocol items for clinical trials. Ann Inter Med. 2013;158(3):200–207. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Gray R, Greenwald R, Hochberg M, Howell D, Ike R, Kapila P, Kaplan D, Koopman W, Longley S, Mcshane DJ, Medsger T, Michel B, Murphy W, Osial T, Ramsey-Goldman R, Rothschild B, Stark K, Wolfe F. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990;33(11):1601–1610. doi: 10.1002/art.1780331101.
    1. Brown S, Thorpe H, Hawkins K, Brown J. Minimization - Reducing predictability for multi-centre trials whilst retaining balance within centre. Stat Med. 2005;24(24):3715–3727. doi: 10.1002/sim.2391.
    1. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2015;25(3):1057–1073. doi: 10.1177/0962280215588241.
    1. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239. 10.1136/bmj.i5239.
    1. StataCorp. Stata Statistical Software: Release 16. College Station: StataCorp LLC; 2019.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren